In India, several centres have been using low dose Rituximab in the Rx of pry MN. Here is a study from AIIMS Delhi https://t.co/WM5h8KbrHy #NephJC https://t.co/urKjVa5HfI
Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience https://t.co/5E6nrGYNvH
@M_Elraggal We had a series of patients where we initially tried this 👇 https://t.co/iAkYeLRkkq
RT @CKJsocial: Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/GAzvpbJbm…
Our paper on Ritux use in 'resistant' MGN... https://t.co/mW9ASt6PFG
RT @CKJsocial: Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/GAzvpbJbm…
RT @CKJsocial: Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/GAzvpbJbm…
RT @CKJsocial: Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/GAzvpbJbm…
RT @CKJsocial: Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/GAzvpbJbm…
RT @CKJsocial: Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/GAzvpbJbm…
RT @CKJsocial: Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/GAzvpbJbm…
Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/GAzvpbJbmg https://t.co/jrP18sycFF
RT @arvindcanchi: Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy. Study from AIIMS, New Delhi. https://t.co/d3j…
RT @arvindcanchi: Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy. Study from AIIMS, New Delhi. https://t.co/d3j…
RT @arvindcanchi: Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy. Study from AIIMS, New Delhi. https://t.co/d3j…
Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy. Study from AIIMS, New Delhi. https://t.co/d3jj9uJYuq https://t.co/sHX63BvYSB
Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience | Clinical Kidney Journal | Oxford Academic https://t.co/FCOOTWR6SN
RT @CKJsocial: Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/6mOBRn78W…
RT @CKJsocial: Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/6mOBRn78W…
RT @CKJsocial: Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/6mOBRn78W…
RT @CKJsocial: Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/6mOBRn78W…
RT @CKJsocial: Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/6mOBRn78W…
RT @CKJsocial: Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/6mOBRn78W…
RT @CKJsocial: Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/6mOBRn78W…
RT @CKJsocial: Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/6mOBRn78W…
Low-dose #Rituximab therapy in resistant idiopathic membranous #nephropathy: single-center experience https://t.co/6mOBRn78W3 https://t.co/bR0vyJavcR